Edition:
United Kingdom

People: Allogene Therapeutics Inc (ALLO.OQ)

ALLO.OQ on NASDAQ Stock Exchange Global Select Market

27.63USD
23 May 2019
Change (% chg)

$-1.40 (-4.82%)
Prev Close
$29.03
Open
$28.31
Day's High
$28.53
Day's Low
$27.54
Volume
208,184
Avg. Vol
120,219
52-wk High
$35.55
52-wk Low
$21.67

Chang, David 

Dr. David Chang, M.D. Ph.D., serves as President, Chief Executive Officer, Co-Founder, Director of the Company. He is a co-founder of Allogene and has served as our President and Chief Executive Officer and as a member of our board of directors since June 2018. Prior to joining us, Dr. Chang served as the Chief Medical Officer and Executive Vice President, Research and Development of Kite from June 2014 until March 2018. Dr. Chang previously held senior positions at Amgen Inc., a biopharmaceutical company, including Vice President, Global Development from July 2006 to May 2014, Senior Director, Oncology-Therapeutics from July 2005 to June 2006 and Director, Medical Sciences from December 2002 to June 2005. Prior to that, he was an Associate Professor at the University of California, Los Angeles School of Medicine. Dr. Chang has served as a member of the Board of Directors of Peloton Therapeutics, Inc., a privately held biopharmaceutical company, since March 2018. He has also served as a Venture Partner of Vida Ventures, LLC since November 2017, and Two River Consulting, LLC since October 2017. Dr. Chang obtained a B.S. in Biology from the Massachusetts Institute of Technology and an M.D. and Ph.D. from Stanford University. Our board of directors believes Dr. Chang’s expertise and experience in the life sciences, including his work in immune-oncology and his educational background, provide him with the qualifications and skills to serve on our board of directors.

Basic Compensation

Total Annual Compensation, USD 362,413
Restricted Stock Award, USD 8,948,150
Long-Term Incentive Plans, USD --
All Other, USD 3,537,970
Fiscal Year Total, USD 12,848,500

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Arie Belldegrun

10,046,200

David Chang

12,848,500

Joshua Kazam

3,592,470

Eric Schmidt

2,588,990

Alison Moore

1,836,610

David Bonderman

--
As Of  31 Dec 2018